The Fresenius Kabi Advantage

Fresenius Kabi’s global roots in making medicines reach back to 1912.

Reliable experience and dedicated support enable you to stay focused on patient care:

100 years of experience
43,000 people employed in over 100 countries
Decades of experience across therapeutic areas

We remain steadfast in our mission to provide high-quality, affordable, and reliable generics and biosimilars to the healthcare providers and patients who depend on us.

Fresenius Kabi’s global roots in making medicines reach back to 1912.

Reliable experience and dedicated support enable you to stay focused on patient care:

100 years of experience
43,000 people employed in over 100 countries
Decades of experience across therapeutic areas

We remain steadfast in our mission to provide high-quality, affordable, and reliable generics and biosimilars to the healthcare providers and patients who depend on us.

Our history

Fresenius Kabi is committed to delivering high-quality biosimilars built on more than 100 years of scientific expertise with a dedication to making therapies more affordable.

Our patient-centric biosimilar development

Our research and development approach centers on broad targets within immunology, oncology, and endocrinology—exploring multiple mechanisms of action to provide cost-saving biologic options for patients with common indications.

State-of-the-art production

Our global expertise in complex medicine, state-of-the-art supply chain, and manufacturing enables us to consistently deliver high-quality biosimilars.

Rigorous testing

Based on the totality of evidence, our biosimilars are approved by meeting the FDA’s requirements for biosimilarity.¹⁻⁶

FDA, U.S. Food and Drug Administration.

References:

1. U.S. FDA. Biosimilar development process. Accessed March 14, 2025.

2. Fresenius Kabi receives U.S. FDA approval for biosimilar Idacio^® (adalimumab). News Release. Fresenius Kabi. December 14, 2022. Accessed March 15, 2025.

3. Fresenius receives FDA approval for their denosumab biosimilars and secures global settlement agreement. March 27, 2025. Accessed May 5, 2025.

4. Fresenius Kabi and Formycon receive U.S. FDA approval for biosimilar Otulfi™ (ustekinumab-aauz). News Release. Fresenius Kabi. September 30, 2024. Accessed May 5, 2025.

5. Stimufend® (pegfilgrastim-fpgk) a Fresenius Kabi biosimilar receives FDA approval. News Release. Fresenius Kabi. September 6, 2022. Accessed March 15, 2025.

6. Fresenius Kabi’s biosimilar Tyenne® (tocilizumab-aazg) becomes the first IV and subcutaneous tocilizumab biosimilar approved by the FDA. News Release. Fresenius Kabi. March 7, 2024. Accessed March 15, 2025.